121 related articles for article (PubMed ID: 25771305)
1. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Jansen MP; Sas L; Sieuwerts AM; Van Cauwenberghe C; Ramirez-Ardila D; Look M; Ruigrok-Ritstier K; Finetti P; Bertucci F; Timmermans MM; van Deurzen CH; Martens JW; Simon I; Roepman P; Linn SC; van Dam P; Kok M; Lardon F; Vermeulen PB; Foekens JA; Dirix L; Berns EM; Van Laere S
Mol Oncol; 2015 Jun; 9(6):1218-33. PubMed ID: 25771305
[TBL] [Abstract][Full Text] [Related]
2. mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers.
Yamamura J; Miyoshi Y; Tamaki Y; Taguchi T; Iwao K; Monden M; Kato K; Noguchi S
Cancer Sci; 2004 Nov; 95(11):887-92. PubMed ID: 15546506
[TBL] [Abstract][Full Text] [Related]
3. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
Van Laere SJ; Ueno NT; Finetti P; Vermeulen P; Lucci A; Robertson FM; Marsan M; Iwamoto T; Krishnamurthy S; Masuda H; van Dam P; Woodward WA; Viens P; Cristofanilli M; Birnbaum D; Dirix L; Reuben JM; Bertucci F
Clin Cancer Res; 2013 Sep; 19(17):4685-96. PubMed ID: 23396049
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Characterization of Immune Cell Infiltration Characteristics and Drug Sensitivity Analysis in Inflammatory Breast Cancer Based on Bioinformatic Strategy.
Zhang Z; Wu H; Shen C; Zhou F
Biochem Genet; 2024 Apr; 62(2):1021-1039. PubMed ID: 37517031
[TBL] [Abstract][Full Text] [Related]
5. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Løkkegaard S; Elias D; Alves CL; Bennetzen MV; Lænkholm AV; Bak M; Gjerstorff MF; Johansen LE; Vever H; Bjerre C; Kirkegaard T; Nordenskjöld B; Fornander T; Stål O; Lindström LS; Esserman LJ; Lykkesfeldt AE; Andersen JS; Leth-Larsen R; Ditzel HJ
NPJ Breast Cancer; 2021 Jan; 7(1):2. PubMed ID: 33398005
[TBL] [Abstract][Full Text] [Related]
6. MICAL-L2, as an estrogen-responsive gene, is involved in ER-positive breast cancer cell progression and tamoxifen sensitivity via the AKT/mTOR pathway.
Wen P; Li J; Wen Z; Guo X; Ma G; Hu S; Xu J; Zhao H; Li R; Liu Y; Wang Y; Gao J
Biochem Pharmacol; 2024 Jul; 225():116256. PubMed ID: 38729448
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory breast cancer biomarkers and biology.
van Golen KL
Int Rev Cell Mol Biol; 2024; 384():63-76. PubMed ID: 38637100
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models.
Rypens C; Van Berckelaer C; Berditchevski F; van Dam P; Van Laere S
Int Rev Cell Mol Biol; 2024; 384():77-112. PubMed ID: 38637101
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial estrogen receptors alter mitochondrial priming and response to endocrine therapy in breast cancer cells.
Karakas B; Aka Y; Giray A; Temel SG; Acikbas U; Basaga H; Gul O; Kutuk O
Cell Death Discov; 2021 Jul; 7(1):189. PubMed ID: 34294688
[TBL] [Abstract][Full Text] [Related]
10. 'Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer'.
J Pathol Clin Res; 2019 Jul; 5(3):213. PubMed ID: 31334921
[No Abstract] [Full Text] [Related]
11. Stanniocalicin 2 suppresses breast cancer cell migration and invasion via the PKC/claudin-1-mediated signaling.
Hou J; Wang Z; Xu H; Yang L; Yu X; Yang Z; Deng Y; Meng J; Feng Y; Guo X; Yang G
PLoS One; 2015; 10(4):e0122179. PubMed ID: 25830567
[TBL] [Abstract][Full Text] [Related]
12. Evolution and functions of stanniocalcins in cancer.
Chu SJ; Zhang J; Zhang R; Lu WW; Zhu JS
Int J Immunopathol Pharmacol; 2015 Mar; 28(1):14-20. PubMed ID: 25816401
[TBL] [Abstract][Full Text] [Related]
13. Characterization of stanniocalcin 1 binding and signaling in gill cells of Japanese eels.
Gu J; Law AY; Yeung BH; Wong CK
J Mol Endocrinol; 2015 Jun; 54(3):305-14. PubMed ID: 25878057
[TBL] [Abstract][Full Text] [Related]
14. Loss of ABAT-Mediated GABAergic System Promotes Basal-Like Breast Cancer Progression by Activating Ca
Chen X; Cao Q; Liao R; Wu X; Xun S; Huang J; Dong C
Theranostics; 2019; 9(1):34-47. PubMed ID: 30662552
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-regulated PTTG1 promotes breast cancer progression by regulating cyclin kinase expression.
Meng C; Zou Y; Hong W; Bao C; Jia X
Mol Med; 2020 Apr; 26(1):33. PubMed ID: 32272902
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer.
Göthlin Eremo A; Lagergren K; Othman L; Montgomery S; Andersson G; Tina E
Sci Rep; 2020 Jan; 10(1):1451. PubMed ID: 31996744
[TBL] [Abstract][Full Text] [Related]
17. Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target.
Qie S; Sang N
J Exp Clin Cancer Res; 2022 May; 41(1):161. PubMed ID: 35501821
[TBL] [Abstract][Full Text] [Related]
18. Prognostic correlation between specialized capillary endothelial cells and lung adenocarcinoma.
Zhao R; Ding Y; Han R; Ding R; Liu J; Zhu C; Ding D; Bao M
Heliyon; 2024 Mar; 10(6):e28236. PubMed ID: 38533005
[TBL] [Abstract][Full Text] [Related]
19. Research progress of STC2 in breast cancer.
Niu X; Zhan Y; Zhang S; Liu Z; Qu C
Biophys Rep; 2021 Jun; 7(3):185-192. PubMed ID: 37287492
[TBL] [Abstract][Full Text] [Related]
20. The impact of RNA binding proteins and the associated long non-coding RNAs in the TCA cycle on cancer pathogenesis.
Shen T; Wang H; Tang B; Zhu G; Wang X
RNA Biol; 2023 Jan; 20(1):223-234. PubMed ID: 37221841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
